Human Papillomavirus Vaccination in Saudi Arabia: A Narrative Review of Current Evidence

沙特阿拉伯人乳头瘤病毒疫苗接种:现有证据的叙述性综述

阅读:1

Abstract

Human papillomavirus (HPV) represents the most common sexually transmitted infection globally, exerting a substantial impact on sexual and reproductive health, with a high oncogenic potential leading to various malignancies. The prevalence of HPV in Saudi Arabia ranges from 9% to 43%, with types 16, 18, and 45 being the most common high-risk strains. Despite the availability of effective vaccines such as Gardasil 9, Gardasil, and Cervarix, proper awareness and vaccination rates remain low in Saudi Arabia. Only 4% of the population has received the HPV vaccine. The Saudi Ministry of Health has integrated HPV vaccines into the national immunization schedule, offering them free of charge and ensuring their availability for adolescent girls and women. However, challenges persist, including cultural and religious beliefs, inadequate healthcare infrastructure, and insufficient public awareness. To effectively increase HPV vaccination coverage, it is crucial to implement comprehensive public education campaigns, actively involve healthcare professionals, and address cultural and religious concerns with sensitivity and respect. International collaboration, such as initiatives by the Gavi alliance and sustained research efforts, is critical to optimizing HPV vaccine efficacy, accessibility, and uptake. Through coordinated efforts, the global burden of HPV-related diseases can be significantly reduced, ultimately leading to improved public health outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。